Aldeyra Therapeutics
ALDX
79 hedge funds and large institutions have $148M invested in Aldeyra Therapeutics in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 21 reducing their positions, and 13 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 21
31% more call options, than puts
Call options by funds: $4.37M | Put options by funds: $3.33M
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
3% more funds holding
Funds holding: 77 → 79 (+2)
4% more capital invested
Capital invested by funds: $141M → $148M (+$6.26M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.68% less ownership
Funds ownership: 65.39% → 59.71% (-5.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.88M |
| 2 |
6CM
683 Capital Management
New York
|
+$3.45M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$1.52M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.06M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$993K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$5.87M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.68M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$2.57M |
| 4 |
Millennium Management
New York
|
-$2.31M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.39M |
ALDX Hedge Fund Activity: Q1 2019 in Review
79 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2019, worth a combined $148M — up 4.4% from $141M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ALDX positions and 13 closed out — a net gain of 2 holders — while 32 added to existing stakes and 21 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.88M. The largest seller was Mangrove Partners, exiting entirely with an estimated $5.87M sold.
- 79 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2019, up from 77 in Q4 2018.
- Funds reported $148M of Aldeyra Therapeutics stock for Q1 2019, up 4.4% quarter-over-quarter.
- 15 funds opened new Aldeyra Therapeutics positions in Q1 2019 and 13 closed out, a net change of +2 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2019 was Adage Capital Partners, an estimated $4.88M added.
- The largest Aldeyra Therapeutics seller in Q1 2019 was Mangrove Partners, an estimated $5.87M sold.
Based on aggregated 13F filings for Q1 2019.